Shares of Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) decreased -0.15% and closed at $0.459 after opening 0.47 with the overall traded volume of 954,169.00 shares. The company’s Market capitalization reached to $32.80 million, $71.51 million outstanding shares. Its low price was $0.44 and highest price was $0.48. The Distance from 50 day Simple moving average was -49.43% and Distance from 200 day Simple moving average -15.49%.The EPS is 0.53.
Threshold Pharmaceuticals, Inc. (THLD) announced interim data from its two Phase 2 proof-of-concept clinical trials of tarloxotinib and outlined its plans to focus company resources on the more clinically-advanced evofosfamide program as well as an earlier-stage anticancer candidate, TH-3424.
“While the response observed in our squamous cell carcinoma of the skin study with tarloxotinib was encouraging, the overall results from the two studies didn’t meet the activity thresholds required to move forward the molecule forward despite the promising results seen in preclinical translational studies,” said Barry Selick, Ph.D., Chief Executive Officer of Threshold. “As a result, we are making no further investment in this program. Instead, we plan to build on the efforts of our collaborator, Dr. Michael Curran of The University of Texas MD Anderson Cancer Center, to demonstrate the potential therapeutic value of adding evofosfamide to immune checkpoint inhibition, to continue to pursue discussions with Japanese regulatory authorities regarding potential registration pathways for evofosfamide, and to advance TH-3424 through IND-enabling toxicology studies with the goal of reaching the clinic in 2017. We plan to provide additional operational guidance in the fourth quarter of 2016.”
Shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) increased 0.73% and closed at $0.468 after opening 0.47 with the overall traded volume of 919,813.00 shares. The company’s Market capitalization reached to $53.64 million, $113.74 million outstanding shares. Its low price was $0.45 and highest price was $0.49. The Distance from 50 day Simple moving average was 5.50% and Distance from 200 day Simple moving average was -58.99%. The EPS is -0.25.
Northwest Biotherapeutics, Inc (NWBO) discovers and develops immunotherapy products to treat cancer in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patients own immune system to attack cancer. The companys products include DCVax-L, which is under Phase III brain cancer trial for treating brain cancer; DCVax-Direct that is under Phase I/II clinical trial for various types of inoperable solid tumor cancers; and DCVax-Prostate, which is under Phase III for prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.